WHO meeting calls for mutant-flu research to be published ‘in full.’

A two-day meeting of 22 experts convened in Geneva by the World Health Organization (WHO) has concluded that two controversial flu studies should be published in full. The research — in which ferret-transmissible strains of avian H5N1 flu virus were created — will be published after a delay of probably a few months, which the experts argue is needed to explain better the public-health benefits of the research and allay public concerns over the safety of the work. “There is a preference from a public health perspective for full disclosure of the information in these two studies,” says Keiji Fukuda, assistant director-general of health security and environment at the WHO. “However there are significant public concerns surrounding this research that should first be addressed.”

The panel, largely made up of flu researchers, also concluded that research into creating more transmissible forms of H5N1 and other flu viruses was important and must continue. They agreed to extend a voluntary 60-day moratorium to allow broader discussions on the biosafety aspects of how such work could best be carried out, given the concerns in many quarters as to the potential consequences of an accidental escape of such viruses from the lab. To this end, the WHO intends to hold further meetings with a broader mix of experts over the next few months.

In December, the US government and the US National Science Advisory Board for Biosecurity (NSABB) had requested that  Nature and Science should not publish the two studies. Fukuda said at a press conference today that since then, there has been more time to reflect, and that in particular, it would be far too complex to redact the details of the papers, and to create a mechanism for disseminating the papers only on a need-to-know basis. The meeting reached consensus on all the major issues, he said, but not the recommendation to publish the study in full, given that some of the US experts present, including Paul Keim, the chair of NSABB, adhered to the US administration’s line.

Philip Campbell, the editor-in-chief of Nature, issued a statement: “Discussions at the WHO meeting made it clear how ineffective redaction and restricted distribution would be for the Nature paper. It also underlined how beneficial publication of the full paper could be. So that is how we intend to proceed.”

See my blog post yesterday — ‘Avian flu controversy comes to roost at WHO’ — and Nature‘s News Special on the H5N1 controversy for more background.

Avian flu controversy comes to roost at WHO

Almost two dozen experts kicked off a two-day international meeting this morning at the World Health Organization (WHO) in Geneva, in a bid to find ways to move forward in the controversy over two studies that have created strains of the H5N1 avian flu virus that are transmissible in ferrets. The meeting may reach some consensus on a few immediate issues, such as what parts of the studies should be published, and who might qualify for access to the full papers on a ‘need-to-know’ basis.

But the narrowness of the expertise of those taking part means that the meeting will not even begin to address the far bigger issue of whether such research should be allowed at all in the future, and if so, how  it should safely proceed. Key to that question is an assessment of the relative public-health benefits, compared to the risks that a proliferation of such research in labs worldwide would increase the risk of an accidental or intentional release of the lab strains. Ferrets are a good proxy for how flu behaves in other mammals, including humans, so any release could itself spark a H5N1 pandemic, with potentially catastrophic consequences given the virus’s likely high mortality rate (see ‘Death-rate row blurs mutant flu debate‘).

The list of experts attending the meeting — which the WHO made public this morning — shows that the panel is overwhelmingly stacked with academic flu researchers, almost all of whom are strongly in favour of such research, and many of whom would like to see it proceed unfettered. By contrast, there are almost no public-health officials of international stature attending, nor experts in risk assessment, biosafety or biosecurity.

The WHO has explained, however,  that the participants were limited to “people who have direct involvement or knowledge about these two studies, their review or oversight, or potential dissemination of results”, and that this meeting has the very limited remit of clarifying “key facts about the two research studies and the most urgent related issues”. 

Continue reading

Pandemic 2009 H1N1 virus gives wings to avian flu

Has the 2009 H1N1 flu pandemic increased the risk that the H5N1 avian flu virus could evolve to create a human pandemic?

That’s a possibility raised by the work of Yoshihiro Kawaoka of the University of Wisconsin, Madison, the main conclusions of which — but not the details — are revealed in a Comment article in Nature today. His team created a virus that has the H5 haemagglutinin (HA) surface protein from the H5N1 virus, with all the remaining genes coming from the 2009 pandemic H1N1 virus. The resulting virus proved to be highly transmissible in ferrets, and is therefore likely to have the same behaviour in other mammals, including humans.

What’s intriguing is that before the 2009 pandemic, several research groups had tried the same experiment, using the garden-variety seasonal H1N1 flu, but without success. The difference is that the 2009 pandemic H1N1 virus, which is a triple reassortant of pig, avian and human viruses, contains the triple reassortant gene (TRIG) cassette, which is believed to make it far easier for a flu virus to swap genes with those from other species. This suggests that H5N1 may find it much easier to reassort with pandemic 2009 H1N1 virus circulating in the wild to create a pandemic virus, whereas it had coexisted with seasonal flu since 1997 without evolving into a pandemic strain, explains Bruno Lina, a virologist and flu researcher at the CNRS, France’s basic-research agency, who works at the University of Claude Bernard Lyon-1.

The study by Kawaoka’s team, which has been accepted for publication by Nature, is one of two studies that have succeeded in creating H5N1 strains capable of transmitting between ferrets. The other, by a team led by Ron Fouchier of Erasmus Medical Center in Rotterdam, the Netherlands, has been submitted to Science. The papers have been at the centre of controversy since 20 December, when the United States government — acting on advice from the US National Science Advisory Board for Biosecurity (NSABB) — asked both journals to publish only the main conclusions of the two flu studies, but not to reveal details. Insights from the research might help to improve pandemic preparedness in the future, but some are concerned that the publication of such work would amplify the risk of an accidental, or intentional, release of the virus that could spark a human pandemic. Flu researchers working on such studies last week declared a 60-day voluntary pause to allow governments and other bodies “time to find the best solutions for opportunities and challenges that stem from the work” (see ‘Pause on avian flu transmission studies‘).

Kawaoka and Fouchier succeeded in creating the transmissible virus in completely different ways. Fouchier used mutation, taking a H5N1 virus and then mutating it until it became transmissible. He initially introduced three mutations, using a technique called reverse genetics, but the resulting virus was not transmissible, so he then took that virus and passaged it through multiple ferrets, a procedure that is known to allow viruses to adapt to their host. The result was a virus with just five mutations, which were enough to make it highly transmissible.

Kawaoka instead used reassortment. He took an HA protein from H5N1 and inserted it into a virus made of up genes from the pandemic 2009 H1N1. The flu virus has eight genes. Two code for the surface proteins HA and neuraminidase (NA), and six code for internal proteins. The eight genes are on separate segments, which means that when two different flu viruses infect the same host, they can swap genes and create new viruses in a process known as reassortment. An H1N1 human and H5N1 avian virus, for example, could generate a new virus that has most of the genes from the human virus, making it transmissible in humans, but an avian haemagglutinin and/or neuraminidase. A largely human virus carrying an H5, to which humans have no previous exposure of immunity, could cause a pandemic if it retained the transmissibility of the human virus, and the lethality of H5N1.

Fouchier’s virus was lethal in ferrets, whereas Kawaoka’s was “no more pathogenic than the pandemic 2009 virus”, and killed none of the animals. A reassortant that occurred in the the wild might have different pathogenicities. But two independent groups have now shown that H5N1 can transmit in ferrets, and so such human-transmissible viruses could potentially arise naturally in avian and other animal populations. What controls the exchange of genes between viruses is poorly understood, says Lina, who himself failed in the past to create highly transmissible reassortants of H5N1 and seasonal H1N1. Triple-reassortant viruses that have this TRIG cassette, of six highly conserved internal genes, seem capable of capturing various HA and NA genes from multiple species, he says. “The pandemic 2009 H1N1 virus has a flexibility of function which makes it capable of associating at the molecular level with virus and gene segments from pig, bird and humans.”

The 2009 pandemic H1N1 is circulating in humans in countries such as Indonesia, China and Egypt, where H5N1 cases in human continue to occur. Co-infection of a person with both viruses would give them opportunities to reassort. Pandemic H1N1 also infects pigs, from which it originally emerged, which could provide further opportunities for reassortment. This emphasizes the need for better surveillance to detect human cases of H5N1 infection.

Monitoring of human cases could also help to prevent flu viruses acquiring human transmissibility. There has been some evidence of limited human-to-human transmission of H5N1 in clusters of human cases, and a virus that passes along even a small chain of human hosts has opportunities to adapt to its host, just as H5N1 did in Fouchier’s ferrets.

But as a news article in this week’s edition of Nature shows (see ‘Caution urged for mutant flu work‘), surveillance of H5N1 in birds worldwide is patchy, particularly in poorer countries, where the virus is prevalent. It is also largely geared towards simply detecting and monitoring outbreaks, and few of the viral samples collected are ever sequenced, with just 160 H5N1 isolates submitted to the GenBank database last year. Moreover, if H5N1 surveillance in birds is poor, the situation is far worse in pigs, where there is virtually no systematic surveillance, even in richer countries. H5N1 infections in pigs are uncommon and cause only mild illness, creating little economic incentive to monitor them — GenBank contains partial sequences from just 24 pig H5N1 isolates in total.

Read all Nature‘s coverage of the issue at the mutant flu special.

Swine flu vaccine and Guillain-Barré syndrome not linked

Posted on behalf of Chloe McIvor.

The adjuvanted vaccines used during the 2009 swine flu (H1N1) pandemic did not significantly increase the risk of Guillain-Barré syndrome, a large, multinational study, commissioned by the European Centre for Disease Prevention and Control (ECDC), concludes today in the British Medical Journal.

The vaccine-related concerns stem from the sevenfold increase in Guillain-Barré syndrome experienced during the US pandemic H1N1 flu vaccine campaign of 1976. Guillain-Barré syndrome is a rare neurological disorder, which can result in severe nerve damage caused by the body’s own immune system. Adjuvanted vaccines contain substances that stimulate the immune system to boost the efficacy of the vaccine. After the 1976 vaccine was abruptly discontinued, flu vaccines became controversially linked to Guillain-Barré syndrome, even though no or little risk was found in studies on subsequent seasonal flu vaccines.

The consortium conducted the study across five European countries which launched vaccination campaigns against the 2009 pandemic; a total sample of 50 million people. They reassuringly found that any risk of Guillain-Barré syndrome is negligible. The risk is estimated to be less than three excess cases of Guillain-Barré syndrome for every million people protected by the vaccine.

Although most current seasonal flu vaccines do not contain an adjuvant, this sort of large-scale safety analysis is important for assessing the potential use of adjuvanated vaccines in the future.

Mixed review for WHO’s handling of the flu pandemic

“Performance fair, but could do better.”

That’s the thrust of an outside review of the World Health Organization (WHO)’s handling of the 2009 H1N1 flu pandemic, by an expert committee which released a preview [pdf] of its findings yesterday.

Twenty-five scientists and public health experts, chaired by Harvey Fineberg, president of the Institute of Medicine of the US National Academies, formed the review committee, and released the preview to solicit comments before the committee’s final meeting on 28 March. Its final report will be presented at the World Health Assembly in May.

The WHO “performed well in many ways,” the committee’s report says. It defends the agency against allegations by critics that industry might have influenced WHO decision-making, including when to officially declare a pandemic. The review “found no evidence of malfeasance”. But it also gives a long list of areas where it says that the WHO could improve its future response to international threats to public health.

Continue reading

Sweden finds no link between flu vaccine and narcolepsy cases

A preliminary investigation by Sweden’s Medical Products Agency of a putative link between GlaxoSmithKline’s Pandemrix pandemic H1N1 vaccine and a handful of cases of narcolepsy – a rare sleeping disorder — has found no evidence of a link. In an update reported 10 September, it says that study of the 22 cases reported from October 2009 to August 2010, shows than any increase in incidence “seems to be of the same magnitude in those vaccinated as in those not receiving any vaccine.”

Twenty of the cases occurred in those younger than 18 years old, whereas normally about 10 cases annually are reported in Sweden in this group, suggesting an increase – though the Swedish agency notes that the numbers are so small that caution is needed in affirming any change from baseline levels.

The European Medicines Agency also launched a review of any link to the vaccine in August following reports of a handful of cases of narcolepsy in Sweden and Finland that occurred shortly after vaccination. Finland has suspended use of the vaccine pending its own inquiry.

Handful of narcolepsy cases sparks pandemic vaccine probe in Europe

The European Medicines Agency launched a review on 27 August of a putative link between GlaxoSmithKline’s Pandemrix pandemic H1N1 vaccine and a handful of cases of narcolepsy – a rare sleeping disorder. A temporal association between vaccination and development of the disease has been reported in 15 children in Finland and six in Sweden, although that by no means proves the vaccine caused them. The review will analyse whether there is any link or not, and whether the cases represent or not an abnormal increase on the usual baseline levels that would be expected: the prevalence of narcolepsy – which has a genetic component, and can be triggered by infections – is estimated generally at around 0.045% of the population, and in Finland 6 cases in children per year.

On 24 August, Finland’s National Institute for Health and Welfare announced on the advice of its National Advisory Committee on Vaccines, that it was suspending vaccination with Pandemrix until the link was investigated. It added that as there’s no flu in the country at the moment, there isn’t any immediate need anyway to vaccinate, while much of the country’s population already has immunity to H1NI either through vaccination or having contracted the virus. The European Medicines Agency will hold a meeting in September to decide whether any provisional measures on the use of Pandemrix are called for pending completion of the investigation.

Side effects of vaccines are part of any public health response risk equation. No amount of clinical trials can detect rare side-effects in advance, as statistically one would need impractically large population-size experimental cohorts to pick up very low incidence rates. Instead, regulators use pharmacovigilance once vaccines have been deployed to spot early on any problems. With some 30.8 million Europeans, including this author, already vaccinated with Pandemrix since autumn 2009, no serious safety concern has been detected.

Although anti-vaccine groups will no doubt leap on the preliminary reports from Scandinavia to scream “side-effects,” the sober reality is that not using modern and safe vaccines causes many more people to become ill or die than any rare side-effect.

H1N1 ‘emergency committee’ members named

who post.jpgThe World Health Organization has released the names of the experts making up its H1N1 emergency committee along with, crucially, their declaration of interests.

Previously the WHO has faced criticism for not releasing these names. Conspiracy theories suggest there could have been collusion between some emergency committee experts and the pharmaceutical industry to award valuable vaccine contracts.

This noise reached its peak with an article in the BMJ earlier this year which rightly noted that the emergency committee advises on the declaration of a pandemic but wrongly claimed that it was this declaring of the pandemic that triggered vaccine contracts. (See: Flu experts rebut conflict claims).

On its part, the WHO maintained that not releasing the names helped buffer the committee from any outside pressure. Now the names are out in the public domain, after yesterday’s announcement that the pandemic is over.

Neil Ferguson, an advisor to the committee named along with the members, told Nature, “I would have been perfectly happy for my name to be made public but I understand the reasons the WHO gave for keeping names confidential.”

Ferguson, who works at the Department of Infectious Disease Epidemiology at London’s Imperial College, adds, “The one lesson that perhaps should be learned is the conspiracy theories show the need for transparency in scientific committees. In retrospect there were perceived issues with transparency and maybe the balance should be drawn differently next time. That’s really for the WHO.”

Committee member Arnold Monto, an epidemiologist at the University of Michigan School of Public Health, says “The lessons are that if possible, full disclosure is the appropriate way to go.”

Extreme rhetoric about the WHO’s connections with the pharmaceutical industry (my favourite being The pandemic that never was: Drug firms ‘encouraged world health body to exaggerate swine flu threat’ courtesy of the Daily Mail) may reduce the willingness of scientists to offer advice when asked, says Monto. Preventing experts from industry, academia and the WHO from working together could harm all parties, he says.

“What we may be undermining is a relationship that exists between industry and public health. If industry doesn’t produce the vaccines we wouldn’t have vaccines,” he says. “I don’t think being totally without connection is either necessary or desirable.”

The WHO is currently conducting its own review of how it handled the H1N1 pandemic. It has already named the members of its review committee.

Ferguson declared having previously worked as a consultant for Roche and GSK Biologicals, stopping this in 2007. Monto declared current and past consultancies in influenza for GSK, Novartis, Roche, Baxter and Sanofi.

In case it needs spelling out: no member declared anything that might be considered even slightly out of the ordinary for an expert on influenza.

Image: WHO

WHO to review handling of H1N1 outbreak

flu.JPGAll Nature’s pandemic flu coverage is collected on our news special page.

The World Health Organization is to review its handing of the swine flu pandemic, as it again comes under attack in Europe over allegations it overhyped the dangers of H1N1.

Keiji Fukuda, the WHO’s special adviser on pandemic influenza, says an independent group will review how well the WHO responded to the outbreak and also whether the risks of the virus were communicated properly. A key issue for the review will be the WHO’s decision to declare a pandemic (Reuters).

“If we look back to the beginning of the pandemic there was a lot of discussion about what do you call these things,” says Fukuda (AP). “These things affect how people perceive outbreaks and pandemics so I think it’s one of those issues that we have to think about.”

The announcement came as the WHO again came under attack for over-hyping the dangers of H1N1. According to the Guardian, the Council of Europe’s health committee is considering a report which currently says the WHO has “gambled away” public faith with its excessively scaremongering pronouncements on H1N1.

“When the next pandemic arises many persons may not give full credibility to recommendations put forward by WHO and other bodies,” says the draft report, according to the paper. “They may refuse to be vaccinated and may put their own health and lives at risk.”

The Parliamentary Assembly of the Council of Europe meets today to discuss swine flu. A previous meeting also dragged up allegations of poor practice at the WHO.

However, the WHO is not without support. Alan Hampson, chairman of Australia’s Influenza Specialist Group, said suggestions the WHO had overreacted were “absolute nonsense” (Sydney Morning Herald). And the Kentucky Department for Public Health has released an advert ridiculing those who doubt the swine flu vaccine (video here).

Too soon to know if H1N1 has peaked, says WHO

flu.JPGAll Nature’s pandemic flu coverage is collected on our news special page.

It is still too soon to say that the swine flu pandemic has peaked, the World Health Organization has warned.

Following a meeting of its emergency committee the WHO declined to change its current pandemic level, leaving it at phase six – widespread human infection. More data is needed before concluding that all parts of the world have passed peak transmission of H1N1, says the committee.

Although there is “mixed evidence” of declining or low activity in a number of countries there is evidence of new community transmission in West Africa, according to a statement from Margaret Chan, the WHO director general.

In its latest update – from 19 February – the WHO noted confirmed cases of H1N1 in over 212 countries, territories and communities.

However, the WHO did make one small step downwards in its Swine Flu Defcon Level. It has changed its recommendation to “intensify surveillance of unusual flu-like illness” to “maintain surveillance of unusual flu-like illness”.

More H1N1 news

“This pandemic appears to be on the less severe side of the spectrum of pandemics that we have seen in the 20th century.”

Keiji Fukuda of the WHO speaks to reporters (Reuters).

“The H1N1 flu pandemic has peaked in most parts of the country, top Chinese epidemiologists said yesterday, even as the World Health Organization (WHO) said the worst was not over internationally.”

China Daily says the pandemic is pretty much over in China.